Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Bellerophon Therapeutics, Inc. | blph-20210331xex31d2.htm |
| EX-31.1 - EX-31.1 - Bellerophon Therapeutics, Inc. | blph-20210331xex31d1.htm |
| 10-Q - 10-Q - Bellerophon Therapeutics, Inc. | blph-20210331x10q.htm |
Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer's knowledge, that:
(1) the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 11, 2021 | By: | /s/ Fabian Tenenbaum |
| | Fabian Tenenbaum Chief Executive Officer (Principal Executive Officer) |
Date: May 11, 2021 | By: | /s/ Assaf Korner |
| | Assaf Korner Chief Financial Officer (Principal Financial Officer) |